Caris Life Sciences Inc - Class A
Research Caris Life Sciences Inc - Class A (CAI) on Bullrun: valuation model: 2.0% overvalued, market cap USD 8.39B, P/E 79.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCAI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal2.0% overvalued
- Market capUSD 8.39B
- P/E79.8
- Financial periodQ2 2026
- RevenueUSD 263.71M
- Net income-USD 637.00K
- Free cash flowUSD 6.40M
- Gross margin68.1%
Valuation Snapshot
Bullrun's latest valuation model marks Caris Life Sciences Inc - Class A as 2.0% overvalued; latest market cap is USD 8.39B; P/E is 79.8.
Peer valuation comparison
Latest P/E is 79.77x versus a Healthcare sector median of 24.61x (224.2% above).
Latest P/E is 79.77x versus a United States median of 23.85x (234.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 812.03M | -USD 68.09M | USD 66.90M | 66.4% | -3.22 | USD 796.27M | USD 378.99M | USD 577.31M |
| FY2024 | USD 412.26M | -USD 281.89M | -USD 253.64M | 43.4% | -10.66 | USD 63.95M | USD 379.53M | -USD 2.50B |
| FY2023 | USD 306.13M | -USD 341.42M | -USD 298.42M | 29.2% | -13.24 | USD 56.40M | USD 217.11M | -USD 2.14B |
| FY2022 | USD 258.49M | -USD 320.83M | -USD 327.96M | 31.0% | -1.57 | USD 107.19M | USD 270.87M | -USD 1.70B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 8.39B | 79.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.61B | n/a | n/a | n/a |
About Caris Life Sciences Inc - Class A
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions;
ETFs that hold Caris Life Sciences Inc - Class A
Caris Life Sciences Inc - Class A is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| Amundi Nasdaq-100 Target Income UCITS ETF EUR Dist | 8.64% | 0.40% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Caris Life Sciences Inc - Class A overvalued or undervalued?
Bullrun's valuation model currently marks Caris Life Sciences Inc - Class A as 2.0% overvalued.
What is Caris Life Sciences Inc - Class A's market cap?
Caris Life Sciences Inc - Class A's market capitalization is USD 8.39B.
What is Caris Life Sciences Inc - Class A's P/E ratio?
Caris Life Sciences Inc - Class A's price-to-earnings (P/E) ratio is 79.8.
What does Caris Life Sciences Inc - Class A do?
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.